Clinical information, including patient demographics, smoking, treatment history, and survival outcomes were obtained from hospital electronic medical records. Prospective histologic predictions of SPLCs versus IPMs were obtained from surgical pathology reports, based on the statement of whether the tumors appeared morphologically similar or different—a routine practice at our institution. Histologic assessment of tumor relatedness was performed by experienced thoracic pathologists based on the histologic criteria proposed by Girard and colleagues (5 (link)). In all cases the histologic predictions were made prior to comprehensive molecular profiling by MSK-IMPACT. The histologic features were re-reviewed by two thoracic pathologists (J.C. Chang and N. Rekhtman).
Progression-free survival (PFS) was calculated using the Kaplan-Meier approach from the time of most recent procedure to the time of progression or death. Patients were otherwise censored at the time of last clinical follow-up. Survival curves between IPMs and SPLCs were compared using the log-rank tests. Analyses were conducted in R 3.5.3 (R Core Team).
Progression-free survival (PFS) was calculated using the Kaplan-Meier approach from the time of most recent procedure to the time of progression or death. Patients were otherwise censored at the time of last clinical follow-up. Survival curves between IPMs and SPLCs were compared using the log-rank tests. Analyses were conducted in R 3.5.3 (R Core Team).
